<![CDATA[Genmab — April 2026]]>Genmab Appoints Margarida Duarte as General Manager, Europe and Emerging Markets https://ir.genmab.com/news-releases/news-release-details/genmab-appoints-margarida-duarte-general-manager-europe-and-emerging-markets

]]>https://dev.proinvestor.com/forum/topic/399207/genmab-april-2026RSS for NodeSun, 07 Jun 2026 02:12:28 GMTWed, 01 Apr 2026 05:32:46 GMT60<![CDATA[Reply to Genmab — April 2026 on Thu, 30 Apr 2026 06:57:17 GMT]]>time frame
for outcome measures all reduced to 1.5yrs for RAINFOL-02 https://clinicaltrials.gov/study/NCT06619236?tab=history&a=18&b=19&compareMode=sideBySide#version-content-panel

]]>https://dev.proinvestor.com/forum/post/7686901https://dev.proinvestor.com/forum/post/7686901Thu, 30 Apr 2026 06:57:17 GMT<![CDATA[Reply to Genmab — April 2026 on Thu, 30 Apr 2026 06:23:01 GMT]]>Jan van de Winkel, Ph.D.

Taking the stage as a keynote speaker at the Antibody & ADC Summit in Shanghai https://www.linkedin.com/posts/janvandewinkel_biotech-innovationinscience-patientimpact-activity-7455280931638132736-2yD1

]]>https://dev.proinvestor.com/forum/post/7686897https://dev.proinvestor.com/forum/post/7686897Thu, 30 Apr 2026 06:23:01 GMT<![CDATA[Reply to Genmab — April 2026 on Thu, 30 Apr 2026 06:14:47 GMT]]>AbbVie Pipeline Update
April 2026
(for Epkinly ) https://investors.abbvie.com/static-files/5bb173b5-053e-4e6e-b028-c82cf2ee96a0

]]>https://dev.proinvestor.com/forum/post/7686895https://dev.proinvestor.com/forum/post/7686895Thu, 30 Apr 2026 06:14:47 GMT<![CDATA[Reply to Genmab — April 2026 on Thu, 30 Apr 2026 05:44:38 GMT]]>and a press release - Denecimig (Mim8) significantly reduced annualized bleeding rate in people with hemophilia A, regardless of inhibitor status, in phase 3 data published in NEJM https://www.prnewswire.com/news-releases/denecimig-mim8-significantly-reduced-annualized-bleeding-rate-in-people-with-hemophilia-a-regardless-of-inhibitor-status-in-phase-3-data-published-in-nejm-302757974.html

]]>https://dev.proinvestor.com/forum/post/7686899https://dev.proinvestor.com/forum/post/7686899Thu, 30 Apr 2026 05:44:38 GMT<![CDATA[Reply to Genmab — April 2026 on Thu, 30 Apr 2026 05:42:16 GMT]]>here is the abstract for that article SugarAlf referred to - The New England Journal of Medicine - Mim8 Bispecific Antibody Prophylaxis in Hemophilia A with or without Inhibitors - https://www.nejm.org/doi/full/10.1056/NEJMoa2517384

]]>https://dev.proinvestor.com/forum/post/7686898https://dev.proinvestor.com/forum/post/7686898Thu, 30 Apr 2026 05:42:16 GMT<![CDATA[Reply to Genmab — April 2026 on Thu, 30 Apr 2026 02:56:49 GMT]]>MIM8 medwatch

]]>https://dev.proinvestor.com/forum/post/7686894https://dev.proinvestor.com/forum/post/7686894Thu, 30 Apr 2026 02:56:49 GMT<![CDATA[Reply to Genmab — April 2026 on Thu, 30 Apr 2026 02:56:37 GMT]]>
Link Preview Image
Novo Nordisk får fine bløderdata med i New England Journal of Medicine

Blødermidlet mim8, der er sendt til godkendelse i USA, er udviklet i samarbejde med Genmab.

favicon

(medwatch.dk)

]]>https://dev.proinvestor.com/forum/post/7686900https://dev.proinvestor.com/forum/post/7686900Thu, 30 Apr 2026 02:56:37 GMT<![CDATA[Reply to Genmab — April 2026 on Thu, 30 Apr 2026 02:37:50 GMT]]>√

]]>https://dev.proinvestor.com/forum/post/7686893https://dev.proinvestor.com/forum/post/7686893Thu, 30 Apr 2026 02:37:50 GMT<![CDATA[Reply to Genmab — April 2026 on Thu, 30 Apr 2026 02:08:00 GMT]]>juni har historisk været en af de svageste måneder for Genmab. Exit-strategi: Trim positionen i juni pga. sæsonmønsteret.

]]>https://dev.proinvestor.com/forum/post/7686892https://dev.proinvestor.com/forum/post/7686892Thu, 30 Apr 2026 02:08:00 GMT<![CDATA[Reply to Genmab — April 2026 on Thu, 30 Apr 2026 02:03:58 GMT]]>Selv købt i går + mere i dag hvis under 1.660 DKK → jeg averager ned i oversolgt område (RSI ~35-38).
Target: 1.850 – 1.900 DKK efter ASCO (slut maj/begyndelse juni).
Forventning: RSI omkring 65 ved det tidspunkt.

]]>https://dev.proinvestor.com/forum/post/7686890https://dev.proinvestor.com/forum/post/7686890Thu, 30 Apr 2026 02:03:58 GMT<![CDATA[Reply to Genmab — April 2026 on Thu, 30 Apr 2026 01:58:12 GMT]]>Petosemtamab
Mulig tidlig update eller trial design (head & neck)

]]>https://dev.proinvestor.com/forum/post/7686896https://dev.proinvestor.com/forum/post/7686896Thu, 30 Apr 2026 01:58:12 GMT<![CDATA[Reply to Genmab — April 2026 on Thu, 30 Apr 2026 01:57:50 GMT]]>Epkinly (epcoritamab)
Opdateringer fra eksisterende studier (f.eks. langtidsdata fra DLBCL/FL)

]]>https://dev.proinvestor.com/forum/post/7686888https://dev.proinvestor.com/forum/post/7686888Thu, 30 Apr 2026 01:57:50 GMT<![CDATA[Reply to Genmab — April 2026 on Thu, 30 Apr 2026 01:57:29 GMT]]>Rina-S (rinatabart sesutecan)
Phase 3 trial design (f.eks. RAINFOL-03 i ovarian cancer) + mulige opdateringer fra tidligere cohorts

]]>https://dev.proinvestor.com/forum/post/7686886https://dev.proinvestor.com/forum/post/7686886Thu, 30 Apr 2026 01:57:29 GMT<![CDATA[Reply to Genmab — April 2026 on Thu, 30 Apr 2026 01:54:55 GMT]]>ASCO 2026: 29. maj – 2. juni (Chicago) kan også være trigger og ofte ser vi stigninger op til asco. 21. maj 2026 (kl. 17:00 ET) → Fulde abstracts bliver frigivet (de fleste).
Her får vi de faktiske data/teaser-resultater.

]]>https://dev.proinvestor.com/forum/post/7686887https://dev.proinvestor.com/forum/post/7686887Thu, 30 Apr 2026 01:54:55 GMT<![CDATA[Reply to Genmab — April 2026 on Thu, 30 Apr 2026 01:46:24 GMT]]>Alternativt, hold dig 100% cash indtil efter regnskabet. Brug de første 30-60 minutter den 8. maj til at vurdere pris + volumen. Det er den laveste-risiko vej lige nu.

]]>https://dev.proinvestor.com/forum/post/7686885https://dev.proinvestor.com/forum/post/7686885Thu, 30 Apr 2026 01:46:24 GMT<![CDATA[Reply to Genmab — April 2026 on Thu, 30 Apr 2026 01:42:28 GMT]]>Du behøver ikke ramme bunden for at lave et godt trade. Fra 1.655 med stop under 1.600 har du en pæn asymmetrisk opside mod 1.800-1.900 (ca. 10-15% potentiale vs 3-4% risiko).

]]>https://dev.proinvestor.com/forum/post/7686891https://dev.proinvestor.com/forum/post/7686891Thu, 30 Apr 2026 01:42:28 GMT<![CDATA[Reply to Genmab — April 2026 on Thu, 30 Apr 2026 01:40:37 GMT]]>FA er priced in, nu handler det om teknisk udvikling. Den faldende trend er ved at miste momentum, og støtten ved 1.650 holder indtil videre. Stort set alle oscillatorer peger på købsmulighed på kort sigt, selvom trenden stadig er nedadgående.

]]>https://dev.proinvestor.com/forum/post/7686884https://dev.proinvestor.com/forum/post/7686884Thu, 30 Apr 2026 01:40:37 GMT<![CDATA[Reply to Genmab — April 2026 on Thu, 30 Apr 2026 01:37:21 GMT]]>Darzalex-royalties og Epkinly-trenden er allerede kendt (stærke Q1-tal fra J&J 14. april).
Ingen pivotal data readouts forventet på selve earnings-dagen.
EPS/revenue vil sandsynligvis lande tæt på konsensus (~0,13–0,16 USD EPS, ~910–925 mio. USD revenue) – ingen kæmpe overraskelse forventet.

]]>https://dev.proinvestor.com/forum/post/7686889https://dev.proinvestor.com/forum/post/7686889Thu, 30 Apr 2026 01:37:21 GMT<![CDATA[Reply to Genmab — April 2026 on Thu, 30 Apr 2026 01:36:29 GMT]]>Regnskabet bliver sandsynligvis neutral-til-let positivt teknisk set (vi er allerede oversolgt), men det store drive mod 2.400 DKK kommer først med de rigtige H2 2026 readouts (Epkinly frontline, Rina-S, petosemtamab). Kort sigt: stadig chance for det savtakkede rebound fortsætter.

]]>https://dev.proinvestor.com/forum/post/7686883https://dev.proinvestor.com/forum/post/7686883Thu, 30 Apr 2026 01:36:29 GMT<![CDATA[Reply to Genmab — April 2026 on Thu, 30 Apr 2026 01:28:02 GMT]]>Miss eller svag outlook → pres ned. RSI ned under 30, og vi kan teste 1.550 – 1.600 DKK support.

]]>https://dev.proinvestor.com/forum/post/7686880https://dev.proinvestor.com/forum/post/7686880Thu, 30 Apr 2026 01:28:02 GMT<![CDATA[Reply to Genmab — April 2026 on Thu, 30 Apr 2026 01:27:30 GMT]]>Regnskab næste uge. Beat + god tone/guidance (især på Darzalex-royalties og pipeline-update) → stærk rebound. RSI(14) fra nuværende ~37 op mod 60-70 inden for 1-2 uger. Pris op mod 1.800 – 1.900 DKK er realistisk.

]]>https://dev.proinvestor.com/forum/post/7686881https://dev.proinvestor.com/forum/post/7686881Thu, 30 Apr 2026 01:27:30 GMT<![CDATA[Reply to Genmab — April 2026 on Thu, 30 Apr 2026 01:19:05 GMT]]>https://nbg1.your-objectstorage.com/proinvestor-dev/forum/boards/132121_GMAB_2026_04_30_09_58_47.png

]]>https://dev.proinvestor.com/forum/post/7686876https://dev.proinvestor.com/forum/post/7686876Thu, 30 Apr 2026 01:19:05 GMT<![CDATA[Reply to Genmab — April 2026 on Thu, 30 Apr 2026 01:17:18 GMT]]>Vi er sandsynligvis tæt på en lokal bund, og en 4-6 ugers optur er plausibel. RSI(14) på 36 er klassisk oversolgt-territorium (under 40), og historisk giver det ofte god rebound-potentiale, især når det ikke har været ekstremt dybt (<30). Et run op mod 60-70 inden for 1-2 uger er helt realistisk i en mean-reversion. Ligesom i 2025 kan vi godt få et savtakket rebound: hurtig op (1-2 uger), lille korrektion, op igen osv. over 4-6 uger.
Se vedhæftede graf https://proinvestor.com/boards/125146/$/132

]]>https://dev.proinvestor.com/forum/post/7686882https://dev.proinvestor.com/forum/post/7686882Thu, 30 Apr 2026 01:17:18 GMT<![CDATA[Reply to Genmab — April 2026 on Wed, 29 Apr 2026 14:17:24 GMT]]>Vil nogen kunne forkare, hvad der skete med kursen i går på ADR noteringen.... Kusen er stødt faldende og den er nede med 0,80% laver kurven et næsten lodret spike til +2,20%. Så 3% op på ca. en halv time, og kursen stabiliserede sig omkring de +2%, og så hen mod luk sev den bare og fortsatte med at sive på det danske marked i dag... - Det er jo langt fra første gang man ser disse mærkværdigheder.... Jeg kunne forstå hvis kursen tager et lodret spike og straks falder tilbage, men det er jo ikke

]]>https://dev.proinvestor.com/forum/post/7686878https://dev.proinvestor.com/forum/post/7686878Wed, 29 Apr 2026 14:17:24 GMT